Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer NCT03992456 Metastatic Colo...
Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Color...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Colo...
Stage IIIA Rect...
Stage IIIB Colo...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Colo...
Stage IIIC Rect...
Stage IV Colon ...
Stage IV Colore...
Stage IV Rectal...
Stage IVA Colon...
Stage IVA Color...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Color...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Color...
Stage IVC Recta...
Unresectable Co...
Unresectable Co...
Unresectable Re...
Panitumumab
Quality-of-Life...
Questionnaire A...
Regorafenib
Trifluridine an...
18 Years - Academic and Community Cancer Research United View Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial NCT03765736 Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Rect...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Rect...
Stage IV Colon ...
Stage IV Rectal...
Stage IVA Colon...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Recta...
Unresectable Co...
Unresectable Re...
Genetic Testing
18 Years - Academic and Community Cancer Research United View Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer NCT04362839 Advanced Colon ...
Metastatic Colo...
Metastatic Colo...
Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Rect...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Rect...
Stage IV Colon ...
Stage IV Colore...
Stage IV Rectal...
Stage IVA Colon...
Stage IVA Color...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Color...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Color...
Stage IVC Recta...
Ipilimumab
Nivolumab
Regorafenib
18 Years - City of Hope Medical Center View Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation NCT05308446 Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Recta...
Stage IV Colon ...
Stage IV Rectal...
Unresectable Co...
Unresectable Re...
Cetuximab
Encorafenib
Nivolumab
18 Years - National Cancer Institute (NCI) View Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer NCT04362839 Advanced Colon ...
Metastatic Colo...
Metastatic Colo...
Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Rect...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Rect...
Stage IV Colon ...
Stage IV Colore...
Stage IV Rectal...
Stage IVA Colon...
Stage IVA Color...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Color...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Color...
Stage IVC Recta...
Ipilimumab
Nivolumab
Regorafenib
18 Years - City of Hope Medical Center View Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer NCT04017650 BRAF NP_004324....
Metastatic Colo...
Metastatic Micr...
Metastatic Rect...
Progressive Dis...
Recurrent Color...
Stage III Color...
Stage IIIA Colo...
Stage IIIB Colo...
Stage IIIC Colo...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Stage IVC Color...
Unresectable Co...
Unresectable Re...
Cetuximab
Encorafenib
Nivolumab
18 Years - M.D. Anderson Cancer Center View A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer NCT05130060 Metastatic Colo...
Metastatic Colo...
Metastatic Colo...
Metastatic Micr...
Metastatic Micr...
Metastatic Rect...
Microsatellite ...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Stage IVC Color...
Colorectal Canc...
Trifluridine an...
18 Years - Mayo Clinic View Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer NCT04017650 BRAF NP_004324....
Metastatic Colo...
Metastatic Micr...
Metastatic Rect...
Progressive Dis...
Recurrent Color...
Stage III Color...
Stage IIIA Colo...
Stage IIIB Colo...
Stage IIIC Colo...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Stage IVC Color...
Unresectable Co...
Unresectable Re...
Cetuximab
Encorafenib
Nivolumab
18 Years - M.D. Anderson Cancer Center View Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer NCT04044430 Metastatic Colo...
Metastatic Colo...
Metastatic Micr...
Metastatic Rect...
Stage III Colon...
Stage III Color...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Colo...
Stage IIIA Rect...
Stage IIIB Colo...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Colo...
Stage IIIC Rect...
Stage IV Colon ...
Stage IV Colore...
Stage IV Rectal...
Stage IVA Colon...
Stage IVA Color...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Color...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Color...
Stage IVC Recta...
Binimetinib
Encorafenib
Nivolumab
Questionnaire A...
18 Years - University of California, San Francisco View Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer NCT04017650 BRAF NP_004324....
Metastatic Colo...
Metastatic Micr...
Metastatic Rect...
Progressive Dis...
Recurrent Color...
Stage III Color...
Stage IIIA Colo...
Stage IIIB Colo...
Stage IIIC Colo...
Stage IV Colore...
Stage IVA Color...
Stage IVB Color...
Stage IVC Color...
Unresectable Co...
Unresectable Re...
Cetuximab
Encorafenib
Nivolumab
18 Years - M.D. Anderson Cancer Center View Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial NCT03765736 Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Rect...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Rect...
Stage IV Colon ...
Stage IV Rectal...
Stage IVA Colon...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Recta...
Unresectable Co...
Unresectable Re...
Genetic Testing
18 Years - Academic and Community Cancer Research United View TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study NCT04109924 Advanced Colore...
Metastatic Colo...
Metastatic Rect...
Recurrent Colon...
Recurrent Color...
Recurrent Recta...
Stage III Colon...
Stage III Color...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Colo...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Colo...
Stage IV Colon ...
Stage IVA Color...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Color...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Color...
Stage IVC Recta...
Unresectable Co...
Unresectable Co...
Unresectable Re...
Irinotecan
Bevacizumab
Trifluridine an...
18 Years - Roswell Park Cancer Institute View Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation NCT05308446 Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Recta...
Stage IV Colon ...
Stage IV Rectal...
Unresectable Co...
Unresectable Re...
Cetuximab
Encorafenib
Nivolumab
18 Years - National Cancer Institute (NCI) View Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study NCT05356897 Metastatic Colo...
Metastatic Colo...
Metastatic Rect...
Stage IV Colon ...
Stage IV Colore...
Stage IV Rectal...
Trastuzumab
Trifluridine an...
Tucatinib
18 Years - Academic and Community Cancer Research United View Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer NCT04362839 Advanced Colon ...
Metastatic Colo...
Metastatic Colo...
Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Rect...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Rect...
Stage IV Colon ...
Stage IV Colore...
Stage IV Rectal...
Stage IVA Colon...
Stage IVA Color...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Color...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Color...
Stage IVC Recta...
Ipilimumab
Nivolumab
Regorafenib
18 Years - City of Hope Medical Center View Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer NCT03592641 Colorectal Carc...
Metastatic Colo...
Metastatic Rect...
Stage III Colon...
Stage III Recta...
Stage IIIA Colo...
Stage IIIA Rect...
Stage IIIB Colo...
Stage IIIB Rect...
Stage IIIC Colo...
Stage IIIC Rect...
Stage IV Colon ...
Stage IV Rectal...
Stage IVA Colon...
Stage IVA Recta...
Stage IVB Colon...
Stage IVB Recta...
Stage IVC Colon...
Stage IVC Recta...
Unresectable Co...
Unresectable Re...
Savolitinib
18 Years - National Cancer Institute (NCI) View